placebo + seasonal TIV

'Placebo + seasonal TIV' refers to a control arm used in clinical trials, specifically in a Phase 1 study (NCT01709019) conducted by Novavax. This combination involves the co-administration of a placebo (typically saline) and a licensed seasonal trivalent inactivated influenza vaccine (TIV). The TIV component is a biologic vaccine containing inactivated influenza virus antigens (hemagglutinin) from three different strains (typically two A strains and one B strain). In the context of the Novavax trial, this arm served as a comparator to evaluate the safety and immunogenicity of the RSV-F protein nanoparticle vaccine (ResVax) when co-administered with a standard flu shot in adults aged 60 years and older.

Other names

placebo + TIVsaline + trivalent inactivated influenza vaccine